TScan Therapeutics
TCRX
89 hedge funds and large institutions have $208M invested in TScan Therapeutics in 2024 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 26 increasing their positions, 17 reducing their positions, and 11 closing their positions.
82% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 11
53% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 17
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
11% more funds holding
Funds holding: 80 → 89 (+9)
0.6% more ownership
Funds ownership: 85.31% → 85.9% (+0.6%)
14% less capital invested
Capital invested by funds: $242M → $208M (-$34.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Checkpoint Capital
San Francisco,
California
|
+$4.98M |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$1.37M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.29M |
| 4 |
BlackRock
New York
|
+$1.03M |
| 5 |
State Street
Boston,
Massachusetts
|
+$895K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LP
LMR Partners
London,
United Kingdom
|
-$3.58M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$2.91M |
| 3 |
PBA
Paradigm Biocapital Advisors
New York
|
-$2.07M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$924K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$859K |
TCRX Hedge Fund Activity: Q3 2024 in Review
89 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in TScan Therapeutics (TCRX) for Q3 2024, worth a combined $208M — down 14% from $242M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new TCRX positions and 11 closed out — a net gain of 9 holders — while 26 added to existing stakes and 17 trimmed.
The largest buyer was Checkpoint Capital, opening a new position worth an estimated $4.98M. The largest seller was LMR Partners, cutting an estimated $3.58M.
- 89 institutional investors held TScan Therapeutics (TCRX) as of Q3 2024, up from 80 in Q2 2024.
- Funds reported $208M of TScan Therapeutics stock for Q3 2024, down 14% quarter-over-quarter.
- 20 funds opened new TScan Therapeutics positions in Q3 2024 and 11 closed out, a net change of +9 holders.
- The largest TScan Therapeutics buyer in Q3 2024 was Checkpoint Capital, an estimated $4.98M added.
- The largest TScan Therapeutics seller in Q3 2024 was LMR Partners, an estimated $3.58M sold.
Based on aggregated 13F filings for Q3 2024.